Intracoronary transplantation of bone marrow stem cells: background, techniques, and limitations

Widimský, Petr; Pěnička, Martin; Lang, Otto; Kozák, Tomáš; Motovska, Zuzana; Jirmář, Radovan; Aschermann, Michael

doi:10.1093/eurheartj/sul067

Cited by 10 publications

(8 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For treatment of heart failure, cells can potentially be delivered to the site of injury where they can repopulate the injured area, integrate into the host tissue, and restore functionality to the myocardium. However, clinical studies have shown that cells delivered by direct injection into the myocardium or by intracoronary injection are rapidly lost [2–4]. Modest improvements in myocardial function have been suggested to merely arise from paracrine effects [5–7].…”

Section: Introductionmentioning

confidence: 99%

2D and 3D Self-Assembling Nanofiber Hydrogels for Cardiomyocyte Culture

Ikonen

Kerkelä

Metselaar³

et al. 2013

BioMed Research International

View full text Add to dashboard Cite

Collagen is a widely used biomaterial in cardiac tissue engineering studies. However, as a natural material, it suffers from variability between batches that can complicate the standardization of culture conditions. In contrast, synthetic materials are modifiable, have well-defined structures and more homogeneous batches can be produced. In this study, several collagen-like synthetic self-assembling nanofiber hydrogels were examined for their suitability for cardiomyocyte culture in 2D and 3D. Six different nanofiber coatings were used in the 2D format with neonatal rat cardiomyocytes (NRCs) and human embryonic stem-cell-derived cardiomyocytes (hESC-CMs). The viability, growth, and functionality of the 2D-cultured cardiomyocytes were evaluated. The best-performing nanofiber coatings were selected for 3D experiments. Hydrophilic pH-sensitive nanofiber hydrogel coassembled with hyaluronic acid performed best with both NRCs and hESC-CMs. Hydrophilic non-pH-sensitive nanofiber hydrogels supported the growth of NRCs; however, their ability to promote attachment and growth of hESC-CMs was limited. NRCs also grew on hydrophobic nanofiber hydrogels; however, the cell-supporting capacity of these hydrogels was inferior to that of the hydrophilic hydrogel materials. This is the first study demonstrating that hydrophilic self-assembling nanofiber hydrogels support the culture of both NRCs and hESC-CMs, which suggests that these biomaterials hold promise for cardiac tissue engineering.

show abstract

Section: Introductionmentioning

confidence: 99%

2D and 3D Self-Assembling Nanofiber Hydrogels for Cardiomyocyte Culture

Ikonen

Kerkelä

Metselaar³

et al. 2013

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…Stem cells are infused through the catheter in one of two manners: (1) nonocclusive angioplasty at slow or high flow rates while maintaining coronary flow or (2) stop-flow method by interrupting it with balloon occlusion [80]. The main advantages are its direct infusion into the target area and the resulting homogenous cell engraftment [131]. …”

Section: Methods Of Stem Cell Deliverymentioning

confidence: 99%

Current Stem Cell Delivery Methods for Myocardial Repair

Sheng

Zhou

Hao

2013

BioMed Research International

View full text Add to dashboard Cite

Heart failure commonly results from an irreparable damage due to cardiovascular diseases (CVDs), the leading cause of morbidity and mortality in the United States. In recent years, the rapid advancements in stem cell research have garnered much praise for paving the way to novel therapies in reversing myocardial injuries. Cell types currently investigated for cellular delivery include embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), and adult stem cell lineages such as skeletal myoblasts, bone-marrow-derived stem cells (BMSCs), mesenchymal stem cells (MSCs), and cardiac stem cells (CSCs). To engraft these cells into patients' damaged myocardium, a variety of approaches (intramyocardial, transendocardial, transcoronary, venous, intravenous, intracoronary artery and retrograde venous administrations and bioengineered tissue transplantation) have been developed and explored. In this paper, we will discuss the pros and cons of these delivery modalities, the current state of their therapeutic potentials, and a multifaceted evaluation of their reported clinical feasibility, safety, and efficacy. While the issues of optimal delivery approach, the best progenitor stem cell type, the most effective dose, and timing of administration remain to be addressed, we are highly optimistic that stem cell therapy will provide a clinically viable option for myocardial regeneration.

show abstract

“…Investigators have begun to tackle the question of cell retention, mostly with discouraging results. Intracoronary delivery of unfractionated BMCs in large animal models and human trials has produced retention rates between 1.3% and 5.3% one to two hours after injection (see Widimsky et al [73] for a review). In a human trial, only three of five patients with acute MI had myocardial engraftment at 20 hours post injection, whereas zero of five patients with chronic MI had engraftment, as monitored by 99m T c-d,l-hexamethylpropylene amine oxime nuclear imaging [74].…”

Section: How Far Have We Come? How Far Have We Come?mentioning

confidence: 99%

Repairing damaged myocardium: Evaluating cells used for cardiac regeneration

Schuldt¹,

Rosen²,

Gaudette³

et al. 2008

Curr Treat Options Cardio Med

View full text Add to dashboard Cite

Cellular cardiomyoplasty has raised hopes of regenerating mechanical function in the heart. Several cell sources have been investigated for their ability to repair the damaged heart, providing reason for optimism. Multiple mechanisms have been proposed for the beneficial effects of the delivered cells; however, true reversal of cardiac damage implies the generation of new contractile myocytes. The assessment of a cell's ability to regenerate contractile cells requires a defined set of criteria that, if met, define success. Here we review data from the four primary players in cellular cardiomyoplasty (skeletal myoblasts, bone marrow cells, embryonic stem cells, and resident cardiac stem cells) and assess their potential to differentiate into contractile myocytes as indicated by their ability to meet such specified milestones. Both animal studies and clinical trials suggest that current experimental approaches to cellular cardiomyoplasty yield short-term improvement, although it may be independent of cell type used. However, the mechanisms underlying this salutary effect, as well as its persistence in the longer term, have remained elusive.

show abstract

Intracoronary transplantation of bone marrow stem cells: background, techniques, and limitations

Cited by 10 publications

References 32 publications

2D and 3D Self-Assembling Nanofiber Hydrogels for Cardiomyocyte Culture

2D and 3D Self-Assembling Nanofiber Hydrogels for Cardiomyocyte Culture

Current Stem Cell Delivery Methods for Myocardial Repair

Repairing damaged myocardium: Evaluating cells used for cardiac regeneration

Contact Info

Product

Resources

About